Charles River Laboratories International, Inc.
CRLHealthcareNASDAQDiagnostics & Research · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, Charles River Laboratories International, Inc. (CRL) is listed under Diagnostics & Research. At a $10.81B market cap, Charles River Laboratories International, Inc. ranks as a large-cap company within healthcare. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
Market Cap
$10.81B
Beta
1.40
P/E (TTM)
—
P/E (Fwd)
18.20
EPS (TTM)
$-3.63
EPS (Fwd)
$12.33
ROE
-5.9%
ROA
4.3%
Cash
$191.8M
Total Debt
$3.06B
Free CF
$510.0M
52W Change
45.2%
Annual Financials
Cash vs Debt
Charles River Laboratories International, Inc. carries $3.06B in total debt against $191.8M in cash reserves — debt is roughly 16.0x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $510.0M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -5.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.3% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $3.54B to $4.02B.
Charles River Laboratories International, Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Charles River Laboratories International, Inc. and its sector.